PMC8019914_01
(A) The lung windows show 2.3 cm x 2 cm nodules with uniform density next to the heart margin of the left lung segment. Contrast-enhanced CT of mediastinal windows shows that the nodules were uniformly strengthened. (B) The PET-CT results of the patient on December 20, 2018, showed a decrease in pleural effusion compared to the PET-CT results on November 21, 2018.
fonc-11-664883-g001.jpg
PMC8019914_01_fonc-11-664883-g001.jpg
f1
Figure 1A ). From November 19, 2018, after admission to the hospital, obvious tumor cells could not be found in the repeated pleural effusion tests ( Figure 2A ). TIGIT is one of the most promising and potential targets in the new generation of immunotherapy drugs, and several anti-TIGIT monoclonal antibodies have been studied. The outcome of the PET-CT scan on December 20, 2018, showed that the patient's pleural effusion improved after bevacizumab treatment ( Figure 1B ).
(A) Scattered lymphocytes, tissue cells, mesothelial cells, and individual atypical cells (H&E staining: original magnification x100). (B) Epithelioid tumor cells distributed in nests and sheets around fibers and blood vessels; some of the cells have transparent cytoplasm with nuclear division (H&E staining: original magnification x100). (C) PD-L1 control (H&E staining: original magnification x100). (D) PD-L1-negative staining.
fonc-11-664883-g002.jpg
PMC8019914_01_fonc-11-664883-g002.jpg
f2
Figure 1A ). From November 19, 2018, after admission to the hospital, obvious tumor cells could not be found in the repeated pleural effusion tests ( Figure 2A ). Positive staining for Ki-67 (approximately 40%), Sy, Melan-A, Hmb45, and S-100 was detected by immunohistochemistry using monoclonal antibodies ( Figure 2B ). We also confirmed that PD-L1 as a target by immunohistochemistry using an anti-PD-L1 IHC 22C3 pharmDx (Dako) antibody ( Figures 2C, D ).
The expression levels of CD8 (green), TIM3 (light blue), PD-L1 (yellow), LAG3 (orange), CD163 (purple), and TIGIT (red) in lung CCS were detected by multiple immunofluorescence assays. The number of positive cells was estimated as follows: TIGIT >=1%, other indexes <1%. CD8 and TIM3 colocalized, and there was no colocalization with other indexes.
fonc-11-664883-g003.jpg
PMC8019914_01_fonc-11-664883-g003.jpg
f3